Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 20% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mrictsurgerytherapybrain
  Phrases that lowered it: lungtrialaminotransferaseuppersingle
• Sponsor's past termination rate: 22% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 25.1% (raises risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 96.3% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 22 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 8950 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 59819 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cisplatin and Pemetrexed With Radiation Followed by Lobectomy NCT01373463 · started 2011 · scored riskier than 97% of active trials terminated
• Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer NCT01860040 · started 2013 · scored riskier than 98% of active trials terminated
• Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC NCT01757288 · started 2013 · scored riskier than 98% of active trials completed
• Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC NCT02275806 · started 2014 · scored riskier than 99% of active trials terminated
• Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer NCT00863512 · started 2009 · scored riskier than 97% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.